CAPiTA study results for Prevenar 13 posted by Pfizer
Pfizer Inc. declared that the outcomes from the (CAPiTA) Community-Acquired Pneumonia Immunization Trial in Adults, which was taken place to assess its hit vaccine namely Prevenar 13, have been circulated in England Medicine Journal of March.
The vaccine Prevenar 13 was developed by Pfizer to provide protection against pneumococcal disease, the most communal source of pneumonia because of bacteria. This infection is one of the major causes of deaths and hospitalization across the globe. This disease can also cause infections in ear and several other children diseases.
Lately, the CAPiTA study was held by the company and the Medical Centre of University located in Holland and Julius Clinical to estimate the vaccination effectiveness of Prevenar 13 in the initial stage of pneumococcal Pneumonia and IPD (Invasive Pneumococcal Disease) and non-invasive community acquired Pneumonia in patients above the age of 65.pateients at this age are mostly more exposed because of their continuously weakening immunity system does not have much ability to fight against to keep them protected from pneumonia and various other diseases.
The Pharmaceutical Companiesdeclared that Prevenar 13 has met all the required endpoints indicated in the study, as it has proven its ability to protect the mentioned age group patients from the life threatening infections.
Almost 84,496 citizens were tested in the CAPiTA study, out of which 50% were provided Prevenar 13, while the remaining was provided a placebo shot. The result came out that Prevenar 13 was able to lower the disease by over 45.6%.
The requirement for the CAPiTA study was set by regulatory authorities of several countries across the globe.
Prevenar 13 is famous and most widely and commonly used vaccine globally for the treatment of pneumococcal disease. Internationally, over 750 million dosages of the vaccine are dispersed and it is the second most profitable drug in the history generating around sales worth of $4.5 billion last year.
The vaccine is by this time permitted in more than 120 countries. The latest approval was provided earlier in February after the European Commission showed green signal to the drug to be directed in adults for treatment of pneumococcal disease.
The United States FDA had already permitted Prevenar 13 to be used in children from 6 weeks to 17 years. The latest printed outcome of the study has also been succumbed to FDA
Moreover, the results have been provided to regulatory authorities of various major international markets like Australia and Canada.
Pfizer stock stood at $34.13 after tumbling by 0.35% throughout pre-market session on 23rd March at 7:52 AM EDT. Wall Street have assigned a price target of $35 on Pfe stock.
The vaccine Prevenar 13 was developed by Pfizer to provide protection against pneumococcal disease, the most communal source of pneumonia because of bacteria. This infection is one of the major causes of deaths and hospitalization across the globe. This disease can also cause infections in ear and several other children diseases.
Lately, the CAPiTA study was held by the company and the Medical Centre of University located in Holland and Julius Clinical to estimate the vaccination effectiveness of Prevenar 13 in the initial stage of pneumococcal Pneumonia and IPD (Invasive Pneumococcal Disease) and non-invasive community acquired Pneumonia in patients above the age of 65.pateients at this age are mostly more exposed because of their continuously weakening immunity system does not have much ability to fight against to keep them protected from pneumonia and various other diseases.
The Pharmaceutical Companiesdeclared that Prevenar 13 has met all the required endpoints indicated in the study, as it has proven its ability to protect the mentioned age group patients from the life threatening infections.
Almost 84,496 citizens were tested in the CAPiTA study, out of which 50% were provided Prevenar 13, while the remaining was provided a placebo shot. The result came out that Prevenar 13 was able to lower the disease by over 45.6%.
The requirement for the CAPiTA study was set by regulatory authorities of several countries across the globe.
Prevenar 13 is famous and most widely and commonly used vaccine globally for the treatment of pneumococcal disease. Internationally, over 750 million dosages of the vaccine are dispersed and it is the second most profitable drug in the history generating around sales worth of $4.5 billion last year.
The vaccine is by this time permitted in more than 120 countries. The latest approval was provided earlier in February after the European Commission showed green signal to the drug to be directed in adults for treatment of pneumococcal disease.
The United States FDA had already permitted Prevenar 13 to be used in children from 6 weeks to 17 years. The latest printed outcome of the study has also been succumbed to FDA
Moreover, the results have been provided to regulatory authorities of various major international markets like Australia and Canada.
Pfizer stock stood at $34.13 after tumbling by 0.35% throughout pre-market session on 23rd March at 7:52 AM EDT. Wall Street have assigned a price target of $35 on Pfe stock.
